Most evidence was present for GLP‐1 receptor agonists, SGLT2‐inhibitors and PPAR‐γ‐agonists for regression of liver fibrosis and MASH. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatohepatitis.